{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brimonidine+Purite&page=2",
    "query": {
      "intervention": "Brimonidine Purite",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 90,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brimonidine+Purite&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brimonidine+Purite&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T00:58:53.734Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02419508",
      "title": "SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Open-Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension",
          "type": "DRUG"
        },
        {
          "name": "Brinz/brim vehicle",
          "type": "DRUG"
        },
        {
          "name": "Prostaglandin analogue",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 290,
      "start_date": "2015-08-07",
      "completion_date": "2018-02-27",
      "has_results": true,
      "last_update_posted_date": "2018-11-15",
      "last_synced_at": "2026-10-03T00:58:53.734Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02419508"
    },
    {
      "nct_id": "NCT00735449",
      "title": "Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%",
          "type": "DRUG"
        },
        {
          "name": "timolol maleate 0.5%",
          "type": "DRUG"
        },
        {
          "name": "latanoprost 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 204,
      "start_date": "2008-07",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2019-04-23",
      "last_synced_at": "2026-10-03T00:58:53.734Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00735449"
    },
    {
      "nct_id": "NCT00121147",
      "title": "Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension",
        "Pseudoexfoliation Syndrome"
      ],
      "interventions": [
        {
          "name": "Travatan",
          "type": "DRUG"
        },
        {
          "name": "Azopt",
          "type": "DRUG"
        },
        {
          "name": "Alphagan P",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hermann Eye Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2003-09",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2006-02-24",
      "last_synced_at": "2026-10-03T00:58:53.734Z",
      "location_count": 21,
      "location_summary": "Los Angeles, California • Hamden, Connecticut • Gainesville, Florida + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00121147"
    },
    {
      "nct_id": "NCT00651612",
      "title": "Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Concurrent brimonidine 0.2% and 0.5% timolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 604,
      "start_date": "2005-11",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2008-04-03",
      "last_synced_at": "2026-10-03T00:58:53.734Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00651612"
    },
    {
      "nct_id": "NCT02039765",
      "title": "Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperemia"
      ],
      "interventions": [
        {
          "name": "Brimonidine tartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-02",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2017-04-28",
      "last_synced_at": "2026-10-03T00:58:53.734Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02039765"
    },
    {
      "nct_id": "NCT00693485",
      "title": "Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma, Open-Angle"
      ],
      "interventions": [
        {
          "name": "400 ug Brimonidine Implant",
          "type": "DRUG"
        },
        {
          "name": "200 ug Brimonidine Implant",
          "type": "DRUG"
        },
        {
          "name": "Sham (no implant)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2008-09",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2013-04-24",
      "last_synced_at": "2026-10-03T00:58:53.734Z",
      "location_count": 1,
      "location_summary": "Artesia, California",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00693485"
    },
    {
      "nct_id": "NCT01170884",
      "title": "Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2009-12",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2019-04-24",
      "last_synced_at": "2026-10-03T00:58:53.734Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01170884"
    },
    {
      "nct_id": "NCT05360784",
      "title": "\"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness\"",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Redness"
      ],
      "interventions": [
        {
          "name": "Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation",
          "type": "DRUG"
        },
        {
          "name": "Lumify® (brimonidine tartrate ophthalmic solution 0.025%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 380,
      "start_date": "2022-05-13",
      "completion_date": "2022-11-23",
      "has_results": true,
      "last_update_posted_date": "2024-08-26",
      "last_synced_at": "2026-10-03T00:58:53.734Z",
      "location_count": 6,
      "location_summary": "Colorado Springs, Colorado • Louisville, Kentucky • Andover, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05360784"
    },
    {
      "nct_id": "NCT01345448",
      "title": "Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Brimonidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo Lotion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nanduri, Padma, M.D., FACS",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2011-04",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2011-05-02",
      "last_synced_at": "2026-10-03T00:58:53.734Z",
      "location_count": 1,
      "location_summary": "Visalia, California",
      "locations": [
        {
          "city": "Visalia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01345448"
    },
    {
      "nct_id": "NCT05294328",
      "title": "Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Presbyopia",
        "Refractive Errors",
        "Eye Diseases"
      ],
      "interventions": [
        {
          "name": "Aceclidine+Brimonidine combination ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Aceclidine ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Proprietary Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LENZ Therapeutics, Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 68,
      "start_date": "2022-05-05",
      "completion_date": "2022-09-10",
      "has_results": true,
      "last_update_posted_date": "2024-09-05",
      "last_synced_at": "2026-10-03T00:58:53.734Z",
      "location_count": 5,
      "location_summary": "Glendale, California • Indianapolis, Indiana • Andover, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05294328"
    }
  ]
}